Elliot, L. N., A. R. Lloyd, J. B. Ziegler, and R. A. Ffrench. 2006. Protective immunity against hepatitis C virus infection. Immunol.Cell Biol. 84:239-249.
Encke, J., J. Findeklee, J. Geib, E. Pfaff, and W. Stremmel. 2005. Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection. Clin.Exp.Immunol. 142:362-369.
Enomoto, N., I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, Y. Ogura, N. Izumi, F. Marumo, and C. Sato. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N.Engl.J.Med. 334:77-81.
Enomoto, N., M. Kurosaki, K. Koizumi, Y. Asahina, I. Sakuma, T. Murakami, C. Yamamoto, F. Marumo, and C. Sato. 1994. [Fluctuation of HCV quasi-species population during interferon therapy; analysis by single strand conformation polymorphism]. Nippon Rinsho 52:1707-1715.
Eren, R., D. Landstein, D. Terkieltaub, O. Nussbaum, A. Zauberman, J. Ben Porath, J. Gopher, R. Buchnick, R. Kovjazin, Z. Rosenthal-Galili, S. Aviel, E. Ilan, Y. Shoshany, L. Neville, T. Waisman, O. Ben Moshe, A. Kischitsky, S. K. Foung, Z. Y. Keck, O. Pappo, A. Eid, O. Jurim, G. Zamir, E. Galun, and S. Dagan. 2006. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 80:2654-2664.
Erickson, A. L., Y. Kimura, S. Igarashi, J. Eichelberger, M. Houghton, J. Sidney, D. McKinney, A. Sette, A. L. Hughes, and C. M. Walker. 2001. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity. 15:883-895.
Esser, M. T., R. D. Marchese, L. S. Kierstead, L. G. Tussey, F. Wang, N. Chirmule, and M. W. Washabaugh. 2003. Memory T cells and vaccines. Vaccine 21:419-430.
Esumi, M., T. Rikihisa, S. Nishimura, J. Goto, K. Mizuno, Y. H. Zhou, and T. Shikata. 1999. Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees. Arch.Virol. 144:973-980.
Fan, X. G., F. Q. Tang, H. Yi, W. E. Liu, M. Houghton, and G. L. Hu. 2000. Effect of IL-12 on T-cell immune responses in patients with chronic HCV infection. APMIS 108:531-538.
Farci, P., H. J. Alter, D. C. Wong, R. H. Miller, S. Govindarajan, R. Engle, M. Shapiro, and R. H. Purcell. 1994. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc.Natl.Acad.Sci.U.S.A 91:7792-7796.
Farci, P., H. J. Alter, D. Wong, R. H. Miller, J. W. Shih, B. Jett, and R. H. Purcell. 1991. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N.Engl.J.Med. 325:98-104.
Firbas, C., B. Jilma, E. Tauber, V. Buerger, S. Jelovcan, K. Lingnau, M. Buschle, J. Frisch, and C. S. Klade. 2006. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 24:4343-4353.
Forton, D. M., H. C. Thomas, and S. D. Taylor-Robinson. 2004. Central nervous system involvement in hepatitis C virus infection. Metab Brain Dis. 19:383-391.
Gerlach, J. T., H. M. Diepolder, M. C. Jung, N. H. Gruener, W. W. Schraut, R. Zachoval, R. Hoffmann, C. A. Schirren, T. Santantonio, and G. R. Pape. 1999. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 117:933-941.
Gerotto, M., F. Dal Pero, G. Bortoletto, A. Ferrari, R. Pistis, G. Sebastiani, S. Fagiuoli, S. Realdon, and A. Alberti. 2006. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J.Hepatol. 44:83-87.
Gish, R. G. 2006. Treating HCV with ribavirin analogues and ribavirin-like molecules. J.Antimicrob.Chemother. 57:8-13.
Gonzalez-Peralta, R. P. and J. Y. Lau. 1995. Pathogenesis of hepatocellular damage in chronic hepatitis C virus infection. Semin.Gastrointest.Dis. 6:28-34.
Goto, J., S. Nishimura, M. Esumi, K. Makizumi, T. Rikihisa, T. Nishihara, K. Mizuno, Y. Zhou, T. Shikata, S. Fujiyama, and K. Tomita. 2001. Prevention of hepatitis C virus infection in a chimpanzee by vaccination and epitope mapping of antiserum directed against hypervariable region 1. Hepatol.Res. 19:270-283.
Grabowska, A. M., F. Lechner, P. Klenerman, P. J. Tighe, S. Ryder, J. K. Ball, B. J. Thomson, W. L. Irving, and R. A. Robins. 2001. Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. Eur.J Immunol 31:2388-2394.
Gramenzi, A., P. Andreone, E. Loggi, F. G. Foschi, C. Cursaro, M. Margotti, M. Biselli, and M. Bernardi. 2005. Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. J Viral Hepat. 12:525-530.
Gruner, T. Santantonio, J. Reichen, G. R. Pape, and A. Cerny. 2000. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cell Immunol. 203:111-123.
Ha, S. J., D. J. Kim, K. H. Baek, Y. D. Yun, and Y. C. Sung. 2004. IL-23 induces stronger sustained CTL and Th1 immune responses than IL-12 in hepatitis C virus envelope protein 2 DNA immunization. J Immunol 172:525-531.
Haller, A. A., G. M. Lauer, T. H. King, C. Kemmler, V. Fiolkoski, Y. Lu, D. Bellgrau, T. C. Rodell, D. Apelian, A. Franzusoff, and R. C. Duke. 2007. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine 25:1452-1463.
Heathcote, E. J., M. L. Shiffman, W. G. Cooksley, G. M. Dusheiko, S. S. Lee, L. Balart, R. Reindollar, R. K. Reddy, T. L. Wright, A. Lin, J. Hoffman, and J. De Pamphilis. 2000. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N.Engl.J.Med. 343:1673-1680.
Herrine, S. K., R. S. Brown, Jr., D. E. Bernstein, M. S. Ondovik, E. Lentz, and H. Te. 2005. Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. Dig.Dis.Sci. 50:719-726.
Hinrichsen, H., Y. Benhamou, H. Wedemeyer, M. Reiser, R. E. Sentjens, J. L. Calleja, X. Forns, A. Erhardt, J. Cronlein, R. L. Chaves, C. L. Yong, G. Nehmiz, and G. G. Steinmann. 2004. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127:1347-1355.
Hoofnagle, J. H. 2002. Course and outcome of hepatitis C. Hepatology 36:S21-S29.
Horsmans, Y., T. Berg, J. P. Desager, T. Mueller, E. Schott, S. P. Fletcher, K. R. Steffy, L. A. Bauman, B. M. Kerr, and D. R. Averett. 2005. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42:724-731.
Isaguliants, M. G., N. V. Petrakova, V. V. Mokhonov, K. Pokrovskaya, Y. G. Suzdaltzeva, A. V. Krivonos, A. D. Zaberezhny, M. M. Garaev, V. D. Smirnov, and E. Nordenfelt. 2003. DNA immunization efficiently targets conserved functional domains of protease and ATPase/helicase of nonstructural 3 protein (NS3) of human hepatitis C virus. Immunol Lett. 88:1-13.
Ishii, K., D. Rosa, Y. Watanabe, T. Katayama, H. Harada, C. Wyatt, K. Kiyosawa, H. Aizaki, Y. Matsuura, M. Houghton, S. Abrignani, and T. Miyamura. 1998. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 28:1117-1120.
Kato, N. 2001. Molecular virology of hepatitis C virus. Acta Med.Okayama 55:133-159.
Klumpp, K., V. Leveque, S. Le Pogam, H. Ma, W. R. Jiang, H. Kang, C. Granycome, M. Singer, C. Laxton, J. Q. Hang, K. Sarma, D. B. Smith, D. Heindl, C. J. Hobbs, J. H. Merrett, J. Symons, N. Cammack, J. A. Martin, R. Devos, and I. Najera. 2006. The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J.Biol.Chem. 281:3793-3799.
Korf, M., D. Jarczak, C. Beger, M. P. Manns, and M. Kruger. 2005. Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors. J Hepatol. 43:225-234.
Lai, M. M. and C. F. Ware. 2000. Hepatitis C virus core protein: possible roles in viral pathogenesis. Curr.Top.Microbiol.Immunol. 242:117-34.:117-134.
Lam, N. P., A. U. Neumann, D. R. Gretch, T. E. Wiley, A. S. Perelson, and T. J. Layden. 1997. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 26:226-231.
Laporte, J., C. Bain, P. Maurel, G. Inchauspe, H. Agut, and A. Cahour. 2002. Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells. Blood ..
Large, M. K., D. J. Kittlesen, and Y. S. Hahn. 1999. Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J.Immunol. 162:931-938.
Lauer, G. M., E. Barnes, M. Lucas, J. Timm, K. Ouchi, A. Y. Kim, C. L. Day, G. K. Robbins, D. R. Casson, M. Reiser, G. Dusheiko, T. M. Allen, R. T. Chung, B. D. Walker, and P. Klenerman. 2004. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 127:924-936.
Lechner, F., N. H. Gruener, S. Urbani, J. Uggeri, T. Santantonio, A. R. Kammer, A. Cerny, R. Phillips, C. Ferrari, G. R. Pape, and P. Klenerman. 2000. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur.J.Immunol. 30:2479-2487.
Lee, S. P. 2003. Chronic hepatitis C. Treatment and side effect management. Adv.Nurse Pract. 11:73-78.
Li, W., D. K. Krishnadas, J. Li, D. L. Tyrrell, and B. Agrawal. 2006. Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immunotherapy. J Immunol 176:6065-6075.
Lin, W., S. S. Kim, E. Yeung, Y. Kamegaya, J. T. Blackard, K. A. Kim, M. J. Holtzman, and R. T. Chung. 2006. Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol 80:9226-9235.
Logvinoff, C., M. E. Major, D. Oldach, S. Heyward, A. Talal, P. Balfe, S. M. Feinstone, H. Alter, C. M. Rice, and J. A. McKeating. 2004. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc.Natl.Acad.Sci.U S A 101:10149-10154.
Lorenzo, L. J., O. Garcia, N. Acosta-Rivero, S. Duenas-Carrera, G. Martinez, J. Alvarez-Obregon, D. Pichardo, A. Ramos, I. Guerra, and J. Morales. 2000. Expression and immunological evaluation of the Escherichia coli-derived hepatitis C virus envelope E1 protein. Biotechnol.Appl.Biochem. 32:137-143.
Major, M. E. and S. M. Feinstone. 2000. Characterization of hepatitis C virus infectious clones in chimpanzees: long-term studies. Curr.Top.Microbiol.Immunol. 242:279-98.:279-298.
Manigold, T., E. C. Shin, E. Mizukoshi, K. Mihalik, K. K. Murthy, C. M. Rice, C. A. Piccirillo, and B. Rehermann. 2006. Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood 107:4424-4432.
Marusawa, H., M. Hijikata, T. Chiba, and K. Shimotohno. 1999. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation. J.Virol. 73:4713-4720.
McHutchison, J. G., K. Patel, P. Pockros, L. Nyberg, S. Pianko, R. Z. Yu, F. A. Dorr, and T. J. Kwoh. 2006. A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J Hepatol. 44:88-96.
McHutchison, J. G., M. L. Shiffman, R. C. Cheung, S. C. Gordon, T. L. Wright, J. C. Pottage, Jr., L. McNair, E. Ette, S. Moseley, and J. Alam. 2005. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. Antivir.Ther. 10:635-643.
Meyer-Olson, D., N. H. Shoukry, K. W. Brady, H. Kim, D. P. Olson, K. Hartman, A. K. Shintani, C. M. Walker, and S. A. Kalams. 2004. Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. J Exp.Med. 200:307-319.
Molinari, M. and A. Helenius. 2000. Chaperone selection during glycoprotein translocation into the endoplasmic reticulum. Science 288:331-333.
Moriya, K., H. Fujie, Y. Shintani, H. Yotsuyanagi, T. Tsutsumi, K. Ishibashi, Y. Matsuura, S. Kimura, T. Miyamura, and K. Koike. 1998. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat.Med. 4:1065-1067.
Mullbacher, A. 1994. The long-term maintenance of cytotoxic T cell memory does not require persistence of antigen. J Exp.Med. 179:317-321.
Nattermann, J., H. D. Nischalke, G. Feldmann, G. Ahlenstiel, T. Sauerbruch, and U. Spengler. 2004. Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine receptor 5. J.Viral Hepat. 11:519-526.
Nattermann, J., H. Zimmermann, A. Iwan, M. Lilienfeld-Toal, L. Leifeld, H. D. Nischalke, B. Langhans, T. Sauerbruch, and U. Spengler. 2006. Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C. Hepatology. 44:945-954.
Nelson, D. R., C. G. Marousis, G. L. Davis, C. M. Rice, J. Wong, M. Houghton, and J. Y. Lau. 1997. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J.Immunol. 158:1473-1481.
Nelson, D. R., C. G. Marousis, T. Ohno, G. L. Davis, and J. Y. Lau. 1998. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 28:225-230.
Netski, D. M., T. Mosbruger, E. Depla, G. Maertens, S. C. Ray, R. G. Hamilton, S. Roundtree, D. L. Thomas, J. McKeating, and A. Cox. 2005. Humoral immune response in acute hepatitis C virus infection. Clin.Infect.Dis. 41:667-675.
Neumann-Haefelin, C., S. McKiernan, S. Ward, S. Viazov, H. C. Spangenberg, T. Killinger, T. F. Baumert, N. Nazarova, I. Sheridan, O. Pybus, F. von Weizsacker, M. Roggendorf, D. Kelleher, P. Klenerman, H. E. Blum, and R. Thimme. 2006. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology 43:563-572.
Nevens, F., T. Roskams, H. Van Vlierberghe, Y. Horsmans, D. Sprengers, A. Elewaut, V. Desmet, G. Leroux-Roels, E. Quinaux, E. Depla, S. Dincq, S. C. Vander, G. Maertens, and F. Hulstaert. 2003. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38:1289-1296.
Neville, J. A., L. E. Prescott, V. Bhattacherjee, N. Adams, I. Pike, B. Rodgers, A. el Zayadi, S. Hamid, G. M. Dusheiko, A. A. Saeed, G. H. Haydon, and P. Simmonds. 1997. Antigenic variation of core, NS3, and NS5 proteins among genotypes of hepatitis C virus. J.Clin.Microbiol. 35:3062-3070.
Ojwang, J. O., S. Ali, D. F. Smee, J. D. Morrey, C. D. Shimasaki, and R. W. Sidwell. 2005. Broad-spectrum inhibitor of viruses in the Flaviviridae family. Antiviral Res. 68:49-55.
Oliver, J. D., H. L. Roderick, D. H. Llewellyn, and S. High. 1999. ERp57 functions as a subunit of specific complexes formed with the ER lectins calreticulin and calnexin. Mol.Biol.Cell 10:2573-2582.
Pancholi, P., M. Perkus, N. Tricoche, Q. Liu, and A. M. Prince. 2003. DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. J Virol 77:382-390.
Pham, T. N., S. A. MacParland, P. M. Mulrooney, H. Cooksley, N. V. Naoumov, and T. I. Michalak. 2004. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J.Virol. 78:5867-5874.
Pockros, P. J., R. Reindollar, J. McHutchinson, R. Reddy, T. Wright, D. G. Boyd, and L. B. Wilkes. 2003. The safety and tolerability of daily infergen plus ribavirin in the treatment of naiive chronic hepatitis C patients. J Viral Hepat. 10:55-60.
Polakos, N. K., D. Drane, J. Cox, P. Ng, M. J. Selby, D. Chien, D. T. O'Hagan, M. Houghton, and X. Paliard. 2001. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J Immunol 166:3589-3598.
Prabhu, R., P. Vittal, Q. Yin, E. Flemington, R. Garry, W. H. Robichaux, and S. Dash. 2005. Small interfering RNA effectively inhibits protein expression and negative strand RNA synthesis from a full-length hepatitis C virus clone. J Med.Virol 76:511-519.
Prince, A. M., B. Brotman, D. H. Lee, L. Ren, B. S. Moore, and J. W. Scheffel. 1999. Significance of the anti-E2 response in self-limited and chronic hepatitis C virus infections in chimpanzees and in humans. J.Infect.Dis. 180:987-991.
Radkowski, M., J. F. Gallegos-Orozco, J. Jablonska, T. V. Colby, B. Walewska-Zielecka, J. Kubicka, J. Wilkinson, D. Adair, J. Rakela, and T. Laskus. 2005. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 41:106-114.
Reesink, H. W., S. Zeuzem, C. J. Weegink, N. Forestier, A. van Vliet, van de Wetering de Rooij, L. McNair, S. Purdy, R. Kauffman, J. Alam, and P. L. Jansen. 2006. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131:997-1002.
Rollier, C., E. Depla, J. A. Drexhage, E. J. Verschoor, B. E. Verstrepen, A. Fatmi, C. Brinster, A. Fournillier, J. A. Whelan, M. Whelan, D. Jacobs, G. Maertens, G. Inchauspe, and J. L. Heeney. 2004. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J Virol 78:187-196.
Rosen, H. R., G. Marousek, and S. Chou. 2002. A longitudinal analysis of T-cell epitope-coding regions of hepatitis C virus after liver transplantation. Transplantation 74:209-216.
Rossi, G., A. Pelizzari, M. Motta, and M. Puoti. 2001. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br.J Haematol. 115:58-62.
Schulze zur, W. J., G. M. Lauer, C. L. Day, A. Y. Kim, K. Ouchi, J. E. Duncan, A. G. Wurcel, J. Timm, A. M. Jones, B. Mothe, T. M. Allen, B. McGovern, L. Lewis-Ximenez, J. Sidney, A. Sette, R. T. Chung, and B. D. Walker. 2005. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol 175:3603-3613.
Shata, M. T., D. D. Anthony, N. L. Carlson, L. Andrus, B. Brotman, N. Tricoche, P. McCormack, and A. Prince. 2002. Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees. J Viral Hepat. 9:400-410.
Sobue, S., T. Nomura, T. Ishikawa, S. Ito, K. Saso, H. Ohara, T. Joh, M. Itoh, and S. Kakumu. 2001. Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. J.Gastroenterol. 36:544-551.
Soguero, C., M. Joo, K. A. Chianese-Bullock, D. T. Nguyen, K. Tung, and Y. S. Hahn. 2002. Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model. J.Virol. 76:9345-9354.
Song, M. K., S. W. Lee, Y. S. Suh, K. J. Lee, and Y. C. Sung. 2000. Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice. J.Virol. 74:2920-2925.
Spangenberg, H. C., S. Viazov, N. Kersting, C. Neumann-Haefelin, D. McKinney, M. Roggendorf, F. von Weizsacker, H. E. Blum, and R. Thimme. 2005. Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. Hepatology 42:828-837.
Steinmann. 2004. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127:1347-1355.
Sugimoto, K., D. E. Kaplan, F. Ikeda, J. Ding, J. Schwartz, F. A. Nunes, H. J. Alter, and K. M. Chang. 2005. Strain-specific T-cell suppression and protective immunity in patients with chronic hepatitis C virus infection. J.Virol. 79:6976-6983.
Takaki, A., M. Wiese, G. Maertens, E. Depla, U. Seifert, A. Liebetrau, J. L. Miller, M. P. Manns, and B. Rehermann. 2000. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat.Med. 6:578-582.
Taura, Y., S. Fujiyama, S. Kawano, S. Sato, M. Tanaka, M. Goto, H. Chikazawa, J. Shibata, K. Mizuno, and T. Sato. 1995. Clinical evaluation of titration of hepatitis C virus core antibody and its subclasses. J.Gastroenterol.Hepatol. 10:270-276.
Taylor, D. R., S. T. Shi, P. R. Romano, G. N. Barber, and M. M. Lai. 1999. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285:107-110.
Thimme, R., H. C. Spangenberg, F. von Weizsacker, and H. E. Blum. T cell response to hepatitis B and C: from viral elimination to hepatocellular carcinoma. 2002. Dtsch.Med.Wochenschr. 127, pág 2277-2279.
Torre, D., C. Zeroli, M. Giola, G. Ferrario, G. P. Fiori, G. Bonetta, and R. Tambini. 1994. Serum levels of interleukin-1 alpha, interleukin-1 beta, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis. Clin.Infect.Dis. 18:194-198.
Tsai, S. L., Y. F. Liaw, M. H. Chen, C. Y. Huang, and G. C. Kuo. 1997. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 25:449-458.
Tsai, S. L., Y. M. Chen, M. H. Chen, C. Y. Huang, I. S. Sheen, C. T. Yeh, J. H. Huang, G. C. Kuo, and Y. F. Liaw. 1998. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 115:954-965.
Ulsenheimer, A., J. T. Gerlach, N. H. Gruener, M. C. Jung, C. A. Schirren, W. Schraut, R. Zachoval, G. R. Pape, and H. M. Diepolder. 2003. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology 37:1189-1198.
Veiga-Fernandes, H., U. Walter, C. Bourgeois, A. McLean, and B. Rocha. 2000. Response of naive and memory CD8+ T cells to antigen stimulation in vivo. Nat.Immunol 1:47-53.
von Hahn, T., J. C. Yoon, H. Alter, C. M. Rice, B. Rehermann, P. Balfe, and J. A. McKeating. 2007. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology. 132:667-678.
Wang, P., J. Du, S. Rachakonda, B. K. Chun, P. M. Tharnish, L. J. Stuyver, M. J. Otto, R. F. Schinazi, and K. A. Watanabe. 2005. Synthesis and structure-activity relationships of novel anti-hepatitis C agents: N3,5'-cyclo-4-(beta-D-ribofuranosyl)-vic-triazolo[4,5-b]pyridin-5-one derivatives. J Med.Chem. 48:6454-6460.
Watashi, K., N. Ishii, M. Hijikata, D. Inoue, T. Murata, Y. Miyanari, and K. Shimotohno. 2005. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol.Cell 19:111-122.
Weiner, A. J., A. L. Erickson, J. Kansopon, K. Crawford, E. Muchmore, M. Houghton, and C. M. Walker. 1995. Association of cytotoxic T lymphocyte (CTL) escape mutations with persistent hepatitis C virus (HCV) infection. Princess Takamatsu Symp. 25:227-35.:227-235.
Widell, A., V. Molnegren, F. Pieksma, M. Calmann, J. Peterson, and S. R. Lee. 2002. Detection of hepatitis C core antigen in serum or plasma as a marker of hepatitis C viraemia in the serological window-phase. Transfus.Med. 12:107-113.
Yi, M., R. A. Villanueva, D. L. Thomas, T. Wakita, and S. M. Lemon. 2006. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc.Natl.Acad.Sci.U.S.A 103:2310-2315.
Yu, H., H. Huang, J. Xiang, L. A. Babiuk, and van Drunen Littel-van den Hurk. 2006. Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3. J Gen.Virol 87:1-10.
Zech, B., A. Kurtenbach, N. Krieger, D. Strand, S. Blencke, M. Morbitzer, K. Salassidis, M. Cotten, J. Wissing, S. Obert, R. Bartenschlager, T. Herget, and H. Daub. 2003. Identification and characterization of amphiphysin II as a novel cellular interaction partner of the hepatitis C virus NS5A protein. J Gen.Virol 84:555-560.
Zein, N. N., H. Li, and D. H. Persing. 1999. Humoral immunity in acute and chronic hepatitis C infection. Gastroenterology 117:510.
Zeuzem, S., J. M. Pawlotsky, E. Lukasiewicz, M. von Wagner, I. Goulis, Y. Lurie, E. Gianfranco, J. M. Vrolijk, J. I. Esteban, C. Hezode, M. Lagging, F. Negro, A. Soulier, E. Verheij-Hart, B. Hansen, R. Tal, C. Ferrari, S. W. Schalm, and A. U. Neumann. 2005. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol. 43:250-257.
Zinkernagel, R. M. 2002. On differences between immunity and immunological memory. Curr.Opin.Immunol 14:523-536.
Autor:
Lic. Julián Triana Dopico
Dr.C Gillian Martínez Donato
gillian.martinez[arroba]cigb.edu.cu
Lic. Yalena Amador Cañizarez
.amador[arroba]cigb.edu.cu
Lic. Julián Triana Dopico
Lugar de nacimiento: Pinar del Río, Cuba.
Estudios realizados: Licenciatura en Bioquímica, Universidad de La Habana, Facultad de Biología.
Profesión: Profesor-investigador, Universidad de Pinar del Río "Hermanos Saíz Montes de Oca", Facultad de Forestal y Agronomía, Departamento de Química.
Dr.C Gillian Martínez Donato
Lugar de nacimiento: Ciudad de La Habana, Cuba.
Estudios realizados: Licenciatura en Bioquímica, Universidad de La Habana, Facultad de Biología.
Profesión: Investigador auxiliar, Centro de Ingeniería Genética y Biotecnología, Departamento de Vacuna contra el VHC, Ciudad de La Habana.
Lic. Yalena Amador Cañizarez
Lugar de nacimiento: Ciudad de La Habana, Cuba.
Estudios realizados: Licenciatura en Biología, Universidad de La Habana, Facultad de Biología.
Profesión: Investigador agregado, Centro de Ingeniería Genética y Biotecnología, Departamento de Vacuna contra el VHC, Ciudad de La Habana.
País, ciudad y fecha correspondiente al trabajo realizado: Cuba, Pinar del Río, Noviembre 2008.
| Página siguiente |